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Having previousiy shown in the Hepnrin Aspirin Reperfusicm 
Trial that the empiric use of early intravenous heparin afier 
raxnnbinant issue-type plasminogen activator Irt.PAI is M im- 
portant component in the overall treatment strategy, se examine 
in lhii report the specific relation between the degree of protan- 
g&n of activated partial tbrotnboptastin time and cornnary 
artery patenry. 
To evaluate the hypc4hesis that arterial pntenev al&r admin- 
istration of r&PA fo;kute nyocxdiat infkction is sustained by 
effective antiw~tion, 8xtivatoC pm-?! :ker&k+stin time of 
heparin miptenls wa determined j and 12 b allor the start of 
thromboiyrir. Mean activated partill thmmtmptastin time wBs 
higher among patients wilh an opa infaret-rciated artery than in 
Ibase with a eiased artery (81 z 4 vs. 54 k 9 I, p < 0.02). Only 
45% of patients with values <45 s at both 8 and 12 h bad 
Tbromtmtyrb In Mymwdtat Infarction (TIMI) flow grade 2 or 3 
in the infarct.ret&d artery at I8 h. In enpd~, 88% of p&en@ 
with activated pa&t tbmmbapkstiu time >4S s and 95% of 
those wi:!! vaius X0 s had an opo tnfaret.related artery at 18 h 
,p = 0.003 and 0.8006, renprtively). 
.4mang patient5 wnb an iniwy patent blfaret.reLted srtwy 
who underwent rept nngipphy at 7 days, activated partial 
thmmboptastii t me was Smiler in those with P per&&ty patent 
artery Blld fhme with ale ree&Luton. weSive ~~t~~ 
did *0t appar to incwse hemwrh@ risk exrep* tkat access 
sitrretated hemorrhage *ar more canlam, in P&eats wilt, a&- 
wed Parttat hrombopla5tin time ZlOO 6 at 8 h. 
TbesP abservatica slppwt tbe view that ektive heparini- 
ticm msintaior cvrorary artery patency after tbmmbeipb with 
r&PA. 
(1 Am Coil Cm,io11992;20:31-5) 
The role ofantithrombins uch as hepxin in the maintenarrce 
of coronary artery Patency after successful thromboiysts 
remains controversial despite the demonstration that the 
coagulation cascade is act&ted by both fibrin-specific and 
nonspecific thromboiytic agents (2). We have previously 
rep&ted (I) that infarct-r&led artery pate& is more 
frequent when intravenous heparin, rather than low dose 
aspirin, is given in conjunction with recombinant issue-type 
plasminagen activator &PA) for treatment of acute myo- 
cardial infarction. The importance af systemic anticoaguia- 
lion with heparin afler thmmboiysis would be further sup- 
ported were infarct-related artery patency more frequent m 
patients with definitely therapeutic levels of anticoagulation 
than among those with low activated partial thrombopiastin 
times T!x possib!e sobstitukw of s~dc~taneo~s hep&n for 
intravenous hepxin would also be affected by any activated 
paniai thrombopiastin time-patency relation, because acti- 
vated partial thrombopiastin time has been rewned to be 
close ;c baseline at i h and barely 1.5 timer laboratory 
contmi value 30 h after the start of subcutaneous adminis- 
tration of heparin (3). 
To evaluaie the relation between systemic anticoaguia- 
lion and the prevention dearly and late reocciusion. s&kl 
activated partial ihromboplastin times were de.cr+aed in 
patients with aente myocardiai infarction receiving n-PA 
and adjunctive intravenous heparin; coronary artery pa!eney 
was assessed at a mean of 18 h and at 7 days after initiatiw 
of thrombolysis. The relation between hemorrhagic events 
during hospitalization and activated partial thmmboplastin 
time ha; & eralttated hecaoje i&venous hepar& has 
been implicated as a contributor to thromboiysis-associated 
hemorrhage (4.5). 
Study objatives. The Heparin Aspirin Reperfusion Trial 
(HART) included three clinical centers with eight hospitals 
and 24 investigators. The principal objective was to deter- 
mine whether i&ret-related artery patency was more fre- 
quent when intravenous heparin or oral aspuin was given in 
conjuwcion with n-P.4 dilring acute myocardial infarction; 
this an$ysis focuses on the group randonuzed to heparin 
therapy. The plimary end points were coronary artery 
patency a: 7 to 24 h and at 7 days. Secondary end points 
included recurrent ischemia (chest pain with ischemic elec- 
trocardrographic IECGI changes or re-elevation of plasma 
creafine kinase leveisl and hemorrhagic events, including 
.ntracerebra.l hemorrhag;, a decrease in plasma hemogiobin 
cf a3 gid1 due tu bleeding at an identified site (excluding 
coronary artery typass surgery-related blood icss) or a 
reduction in hemoglobin of 4 gldl without an identified site. 
Study design. Patients presenting within 6 h of onset of 
chest pain were eligible for entry if 0. I mV ST elevation was 
identified in two contiguous Icads arid if none of the follow- 
ing exclusion criteria were present: severe hypertension, 
cerebrovascular disease, bleeding disorders, previous coro- 
nary artcry bypass surgery, recent surgery or prolonged 
cardiopulmonary resuscitation, other serious medical ill- 
nesses, pregnancy or cunent oral anticoagulant reatment. 
Patients provided informed consent on a form approved by 
the lnstirutional Review aosrds of the participating hospi- 
tals. 
Patients received I@3 mg of n-PA (a 6 mg boiur dose. 
$4 mg during the 1st h, 20 rug during the 2nd h and 5 m@h 
during each of the next 4 h), then were randomized to 
treatment with oral asp+. (80 mgiday) or intravenous hep- 
arin (5,OOU IU bolu: followed by infusion at l.OfN Ill/h, 
adjusted IO maintain activated partial thromboplastin time at 
1.5 to 2 limes the control value). Adjunctive treatment was 
started zt the beginning of the rt-PA infusion. Infarct-related 
artery patency was determined 7 to 24 h (mean 18 h) after 
initiation of rt-PA and on the 7th hospital day. For patients 
assigned to heparin, the infusiul: rate was reduced by 50% 
for 2 to 3 h before catheterization. Angiagrams were inter- 
preted at the Core Laboratory by a single observer (A.M.R.) 
who had ‘10 knowlcdee of treatment arm or aneionraohic 
timing: arteries were jidged closed in patients w<h ?hrom- 
bolysis iii Myocardial Infarction (TIMI) flow grade 0 or I and 
open in patients with TIM: flow grade 2 or 3 (6). 
Activafed purtiol thromboplastin time was determined 
with use of Aclin SS (Dade) at baseline, 8 and I2 h after 
initiation of R-PA treatment, daily thereafter and 3 h after 
any change in heparin infusion rate. 
Statistical analysis. Continuous variables sre expressed 
as mean value f SE. End points were tabulated and com- 
pared with chi-square or Fisher two-tailed exact test for 
discrete variables and by twu-tailed f test for continuous 
variables. Logistic regression was used for multwariate 
analysis. 
Coronary artery patawy and activated partial thmmbo. 
plastin time. Coronary angiography was performed at 18.3 
z 0.8 h after the start of R-PA infusion in the hen&r eroun. 
Five patients did not undergo angiography: one &xtienihada 
stroke, two patients rcfuscd the pmccdure and two were 
withdrawn from the study by their physicians. One addi- 
tional patient in excluded from analy& because the infarct- 
related arterv cmld non he identiiied. Amonr! the 100 ~a- 
tients randor&ed to heparin therapy with an&able Ii-h 
angiognms, 94 had activated partial thmtnbnplastin time 
available at baseline and nt 8 and 12 h. Among patients with 
a closed infarct-related artery, that is, TIMI Row grade 0 or 
I, the mean activated partial thromboplasrin time at 8 h was 
lower than in the group with open art&es (TIM1 flow grade 
2 or 3) (Table I). 
Results 
Subtherapeutic activated partial thromboplastin time at 8 
or 12 h or both 8 and 12 h was more common among patients 
with an occluded infarct-related artery (Table I). Of the II 
patients randomized to receive intravenous hcparin who had 
activated partial thromboplastin time <45 s at both g aud 
12 h. only 5 (45%) had a patent n”ery at 18 h. In contrast, 
patients with persistently therapeutic values between throm- 
FToloagation cd activated partial thmmboplastin time. A 
!otal of 205 patients were enrolled; 106 were randomized to 
heparin and 99 to zspirin therapy. Activated partial throm- 
boplastm tnnes were not requtred by promcol in patients holys!s and angiography were more likely lo have an open 
randomized to aspirin therapy, but baseline values were 
available fx92 (92%) of99 and for I64 (98%) of It36 palien& 
in rhc heparin group. Mean values were Eimilar in the two 
treatmen: mups at baseline. 30 + I versus 31 + I 5 for 
hcpalin aid a&in. respectively, and no di5erent from 
laboratorv contml values. Amone natienls receivim? hep- 
arin, act&ted partial thromhopl& time was significantly 
prolonged 8 h (76 + 4 s) and I2 h (73 2 4 s) after initiation of 
rt-PA therapy (p < 0.001 vs. baseline). In contrast, mean 
activated partial thrombnplastin time at 8 h in the aspirin 
group was 42 i 4 s (n = 83, p < 0.0131 vs. the heparin group 
at 8 h). 
PTT. sot 
artery: 54 (RS%) of 61 patients with aciivated parhal throm- 
book&in time 245 sat 8 and I2 h and 37 lYS%I of 39 D&B:E 
wiih a value X0 sat bath times hod a patent arter; at 18 h 
(Fig. I). 
The relation between Partial tbromboplastin time and 
coronary artery patency was maintamed fp = 0.025) in the 
presence ofother variables (age. gender. clinical site. time to 
artgiogwhy and time to treatment); none of these variables 
was signitizantly related to arterial patency. 
Partial thromboplastitt lime and arterial patency at 7 days. 
Of the IO0 patients treated with thepatio who had angiogmms 
at I8 h. 82 had a patent infarct-related artery and thus ‘were 
eligible for pm&ol angiognphy at 7 dais. Of these 82 
patients, 11 umie~ent coronary revarcularization in the 
interval; IO other patients refused (or their phyrician re- 
fused) the second angiogram and ! patient died. Among the 
60 patients undergoing repeat angiography, the infarct- 
related artery remained open in 53 and had closed in 7. Mean 
activated partial thfomboplastin time (58 Z I s vs. 57 5 4 s 
for open and closed arteries, respectively). the proportion of 
values that .vere subtherapeutic (202 [30%1 of 682 vs. 29 
[33%1 of 87) and the proportion of patients with one or more 
subtherapeutic activated partial thromboplastin times (51 of 
53 vs. 7 of 7) did not direr between the groups with an open 
wsos a closed infarct-related artery at the second angio- 
graphic study. 
Valuer >I00 E were observed in 22 of 101 and 16 of NO 
patients a! 8 and 12 h. respectively attcr the E’?T~ of n-PA 
infusmn. Among patients with activated partial thmmboplar 
tin time > IO0 I. rhe proportion with any type of hemonh~gi: 
event 15 of 22 at 8 h, 3 of 16 at I2 h and 6 of 25 at either 8 or 
I2 hldid notdillerfmmthatinthegroup with values ~IMts. 
The proportion of patients with access site-related hemor- 
rhage was grealer among those with activated partial throm- 
boplastin time >tW I at 8 h than that in the group wirh 
wlues 5 IO s (4 of 22 vs. 2 of 78, p = 0.02 by Fisher exact 
test). By I2 h &er initiation of rt-PA theraps. the relation 
between access site hemorrhagic events and activated partial 
thromboptastin tmte was no longer apparent. 
Hemorrhage and partial IhrwnbopIastin time. Of the pa- 
tients who received heparin. five had bleeding at puncture 
rites (related to angiagraphy in three and at other access 
sites in two) and nine had nonaccess-related hemorrhagic 
events mclildmg six patients who had no identified site of 
blood loss. but had at last a 4 gldl decxase in hemoglobin; 
one vatient each had aastrointestinal. subcanior.c:ival and 
retroieritoneal hemorrhage. Mean activated &ial throm- 
boplastin time at 8, 12 and 24 h did not differ between 
patients with and without hemorrhagic events (Table 2). 
Discussion 
The major finding in rhis study IS the strong relation 
between acrivated partial thromboplastin time during the 
interval between thrombolysis and coronay angiography at 
I8 h and ::.; fxi;qucnsy ofi&trc:-related artery patency: 45% 
to pattents with.activated parttal thromboplnsiki tiroc <45 P 
at g and I2 h, 88% in those with values 245 s and 95% m 
those with values >M) s. Activated partial thromhoplastin 
time did not predict hemorrhagic risk except that access 
site-related hernarrhage was more common in patients with 
valoes >Itm s. 
Coronary artery patency at 18 It. Although toe HART did 
not sludy reocclusion itself, but rather patency 18 h after rhe 
starl of therapy. the reduced patency rate among patients 
with subtherapeutic activated partial thromboplanin time 
can be attributed to rethmmbosis because it ins been 
repea:cd,y shown that 75% to 85% of infarct-related art&s 
are patent at 90 min after the start of rt-PA infusion (7-9). A 
relatively wndll number of patients were observed to have 
persirtently sublherspeutic values. reflecting adherence by 
~nvertigators to the protocol requirement that aclivated 
partial thrnmhnplastin time be maintained at 1.5 to 2 time? 
the control level: no effort was made in the !?ART WI 
~ros~ect~~el~ compare altcrnativc hcparm regimens or tar- 
set &ia! Ih&b~plastin lima. Il:bi patients are classified 
into two proups, those wit5 values <2 times the contrnl 
value at Sand~ll h and those with values ;2 times control, 
the respxtive patency rates are 75% and 95%. These values 
are co&lent with the European Cooperat~e Study Group 
Hcoarin Trial WSG-6) to which awiography at a mean of 
$1 in demonnlrated 72% of arteries to he patent in patients 
with inadequate heparinization, defined as at least one 
activated p-tied tbromboplastin time < 1.3 times baseline, 
with samp!es collected at 3, 12. 24 and 36 h; in contrast, 90% 
of arteries were patent in patients in whom all values were 
>2 times control Werstraete M, personal communication, 
1991). Futther. in the TIM1 II trial 110) activated partial 
thromboplastin times at 5 to I2 h were longeetamoog patients 
with a patent than in those with an occluded infarct-related 
artery ai angiog~aph) pcrforreed a! !B to 48 b. 
Ctiniest aequetae aP coronary rwcctusiun. Additional sup 
port for the importance of therapeutic heparinization in the 
maintenance of coronary artery patency afier thrombolysis 
was provided by Kaplan et al. (Ii), who reported that 
recu~wnt isrhemia after lhrombolp!ic therapy was 6 limes 
more likely IO he associated with activated partial thrombo- 
piastin nme -so I than wnh values > 100 s. Reocclusion has 
been associated with a markedly adverse outcome, whereas 
infarc-related artery patency has generally hecn associated 
wtth a more favorable prognosis (12,13). In contrast to the 
low 4% monality rate in patients wkh reperfusion at a90 o?in 
and with subsequentlv vrcscrved patency. the fatality rate 
has been rep&d (;4j to be threef& higher in pati& with 
early reocclusion (12.8%. p = O.ot), underscoring the clini- 
cal impoflance of appropriate adjunctive therapy after ini- 
tially successful thromholysis. 
The present results also potentially affect the unresolved 
debate between advocates of early inlrwenous wsus suh- 
cutaneous beparin after lylic therapy, at least with rt-PA. 
Reocclusion of the successfully rcperfused infarcr-related 
anery occurs predominantly during the 1st I2 to 24 h (12). 
We have demonstrated that maintcr.aeca of a therepeutis 
ro!ivared pm’tial tlwmhoplastin time during that interval 
Hull et al. (IS) that 29% afpaoents rcccivmg hcparin (28.484 
W/day) had whthenpeutic levels arter?4 h and I[ :.eggests 
that optimal preservation of patency after thrombol+is 
might require a more aggressive anticoagulation regimen. 
Anv ootential benefit would have to he weighed ac&t the , 
prerumptivc increase in hemorrhagic risk. - 
Patients in the HART who were randomized to the 
heparin group did nor receive aspirin, an agent that might 
have reduced the &cw~ncy of rethromboris. The ECSGd, 
which compared hepsrin iod aspirin (250 to 300 mg) with 
aspirin alone, also demonstrated arterial patency to he more 
common srnong patienls with activated partial thromboplas- 
tin >2 times the control level, suggesting that the addition of 
aspirin to heparin will not compensate for inadequate hcpa- 
riniration. One possible explanation for these observations 
iy that aspirin does not inhibit thrombin-mediated platelet 
aggregation, and thrombin is thought to he the primary local 
stimulant to aggregation in this clinical setting. 
Patency at 7 days. In contrast lo the findinss al 18 h. the 
extent of anticoagulaiion after I8 h did not affect patency at 
7 days, an ohse&tion conwtettt with the National Heart 
Foundation of Australia study (16) in wbsh 202 patients 
received n-PA and intravenous heparin for 24 h. then were 
assigned to continue heparin or to receive aspirin and 
dipyridamoie. arsenal patency (80%) and remfarction at 7 
days were similar in the two groups. in a smaller study, 
Kander et al. (17) randomized patients with TIM1 grade 3 
flow and without vistble rhrombus after either thrombolvsis 
oracute aogioplasry to receive intravenous heparin for eiihsr 
24 or 72 h; patency at I week was the same in the two 
groups. Thus., although neither of these studies was defini- 
tive, they suggest hat intravenous heparin is less necessary 
a!ter the 1st IR to 24 h. 
Conclusions. Infarct-related coronary artery patency at 
any time represents a snapshot of a dynamic event ir.z!91: : 
dissolution ;wd reformation of intracoronary thrombus. 
There has been a suspicion that nonfibrin-specific activators 
such as streptokinase, which induce high levels of anticoag- 
ulaot fibrinogen and fibrin degradation products, may be less 
dependent on adjunctive measures to prevent reocclusion 
than are fibrin-specific activators such as r&PA. However, 
the validity of such assumpttons htts 1131 been documented. 
Optimally, the most advantageous regimer. for each plas- 
minogen activator should be identified and included in trials 
comparing thromholytic agents. However, as far as lihrin- 
increasescoronary artery patency. Turpie et al. (3) reported specific agents are cnnrernPd. our findings add to the grow- 
that 6 h after startine admmistration ofsubcutaneous heoarin ine evidence that vieorous antiihrombotic :h:r.w with 
(12,5W IU lwice daily), the activated partial thrombop~~stin he&n is a necessary~adjunct. 
time was haiely above control levels. At 24 h, actiwted 
partial thromhoplastin time remained subtherapeutlc in the 
majority of patients receiving I0CQ IU twice daily even 
after an intravenous holus of 5.0 LU. References 
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